Abstract
A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post-transplant lymphoproliferative disorder in adult recipients of solid organ transplants. This review details the therapeutic options recommended including reduction in immunosuppression (RIS), transplant organ resection, radiotherapy and chemotherapy. Effective therapy should be instituted before progressive disease results in declining performance status and multi-organ dysfunction. The goal of treatment should be a durable complete remission with retention of transplanted organ function with minimal toxicity.
Original language | English |
---|---|
Pages (from-to) | 693-705 |
Number of pages | 13 |
Journal | British Journal of Haematology |
Volume | 149 |
Issue number | 5 |
DOIs | |
Publication status | Published - Jun 2010 |
Keywords
- lymphoproliferative
- transplant
- therapy
- chemotherapy
- MONOCLONAL-ANTIBODY RITUXIMAB
- B-CELL LYMPHOMA
- DOSE-ADJUSTED EPOCH
- CYTOTOXIC T-CELLS
- ANTI-CD20 ANTIBODY
- ELDERLY-PATIENTS
- SINGLE-CENTER
- HEART-TRANSPLANTATION
- LUNG TRANSPLANTATION
- ARGININE BUTYRATE